TABLE 1.
Baseline characteristics of the healthy control, HCM patients, and AL CA patients.
| Characteristics | HA (n = 17) | HCM (n = 16) | AL CA patients (n = 38) | P (HA vs. HCM\HA vs. CA\HCM vs. CA) |
| Male/female | 9¥8 | 14/2 | 28¥10 | – |
| Age (years) | 58.4 ± 7.3 | 49.2 ± 13.7 | 61.9 ± 8.4 | 0.017*¥0.389¥0.016* |
| Mayo stage (I/II/IIIa + IIIb) | – | – | 20/4/14 | – |
| cTnI (μg/L) | 0.000 (0.000–0.001) | 0.062 (0.008–0.117) | 0.038 (0.005–0.055) | <0.001**¥<0.001**¥0.02* |
| NT-proBNP (g/ml) | 0 (0–8) | 525 (75–847) | 1,758 (45–2,755) | <0.001**¥<0.001**¥<0.001** |
| HTN¥DM¥CHD | – | 5/0/0 | 18/6/8 | – |
| CMR | ||||
| LV EF (%) | 62.2 ± 5.8 | 71.4 ± 8.0 | 64.2 ± 11.0 | 0.014*¥0.203¥0.152 |
| Index LVEDV (ml/m2) | 74.2 ± 9.6 | 64.6 ± 14.3 | 66.6 ± 21.3 | 0.001*¥0.057¥0.216 |
| Index LVESV (ml/m2) | 28.6 ± 6.9 | 19.0 ± 8.8 | 26.8 ± 15.0 | 0.045*¥0.551¥0.138 |
| LV MI (g/m2) | 37.4 ± 5.5 | 72.7 ± 22.5 | 59.4 ± 16.5 | 0.001**¥0.004**¥0.359 |
| LVMWT (mm) | 6.1 ± 0.7 | 18.8 ± 3.3 | 14.9 ± 2.7 | <0.001**¥<0.001**¥0.297 |
| LVLGE (none/patchy/extensive) | – | 1/15/0 | 10/12/16 | – |
| LV GRS (%) | 45.2 ± 9.4 | 38.3 ± 12.0 | 32.8 ± 11.7 | 0.563¥0.405¥0.891 |
| LV GCS (%) | −21.2 ± 1.8 | −15.0 ± 3.2 | −18.0 ± 3.3 | <0.001**¥0.057¥0.567 |
| LVGLS (%) | −16.8 ± 1.2 | −9.5 ± 1.8 | −11.2 ± 3.3 | <0.001**¥<0.001**¥<0.001** |
| Native T1 (ms) | 1,243.5 ± 29.5 | 1,318.2 ± 32.4 | 1,374.6 ± 79.4 | <0.001**¥<0.001**¥0.006* |
| ECV (%) | 30.1 ± 2.5 | 31.3 ± 3.4 | 42.8 ± 11.5 | <0.001**¥<0.001**¥<0.001** |
All continuous variables are presented as mean ± SD, except for cTnI, NT-proBNP, which are presented as medians (quartiles 1 to quartiles 3). *P < 0.05, **P < 0.001, statistically significant difference. AL CA, cardiac light-chain amyloidosis; HCM, hypertrophic cardiomyopathy patients; HA, healthy control subjects; cTnI, Cardiac Troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; HTN, hypertension; CHD, coronary artery heart disease; DM, diabetes mellitus; MR, magnetic resonance; LVEF, left ventricle ejection fraction; LVEDV, left ventricle end-diastolic volume index; LVESV, left ventricle end-systolic volume index; LV MI, left ventricle mass index; LGMWT, left ventricle maximum wall thickness; LGE, late gadolinium enhancement; GCS, global circumferential strain; GLS, global longitudinal strain; GRS, global radial strain; ECV, extracellular volume.